1. Introduction {#s0005}
===============

Most mitochondrial proteins are encoded by nuclear DNA and produced by ribosomes outside this organelle [@b0005]. Numerous proteins directed to the mitochondrial matrix, intermembrane space or internal membrane are synthesized with an extended N-terminus, a signal sequence, which is cleaved-off by specific mitochondrial peptidases [@b0010]. The mitochondrial processing peptidase (MPP; EC 3.4.24.64) is the most important processing enzyme that acts on proteins directed to the inner membrane, inter-membrane space or mitochondrial matrix. Most of the proteins targeted to the mitochondrial matrix or inner membrane present a single cleavage by MPP. However, in the mitochondrial matrix, some proteins also take a second sequential cleavage by the mitochondrial intermediate peptidase (MIP; EC 3.4.24.59). In these proteins, MIP removes eight residues from the newly generated N-terminus after the MPP action [@b0015; @b0020; @b0025; @b0030].

Human MIP (*h*MIP) is encoded by a nuclear gene (MIPEP), and is transported to the mitochondria. It also presents a signal sequence of 35 residues that is cleaved by MPP. MIP is a soluble monomer of about 75 kDa with the typical zinc ion binding motif, HEXXH [@b0035]. The higher levels of *h*MIP expression were detected in tissues that consume oxygen at a high rate, i.e. in heart and skeletal muscle, and in several regions of the brain [@b0040]. This peptidase was identified in many mammals and other species too [@b0025; @b0045; @b0050; @b0055; @b0060]. The enzyme from *Saccharomyces cerevisiae*, formerly known as yeast mitochondrial intermediate peptidase (*y*MIP) but now called octapeptidyl amino peptidase 1 (oct1), is the best characterized mitochondrial intermediate peptidase. According to the N-terminal end rule, the action of oct1 is important to the stability of the oct1 processed proteins in the mitochondrial matrix [@b0065; @b0070]. This hypothesis arises from the observations of the amino terminal sequences from the processed proteins by this enzyme, before and after the oct1 action, and, from the direct analysis of the stability of three known oct1 processed proteins in a Δoct1 *S. cerevisiae* [@b0070]. Thus, oct1 converts unstable precursor intermediates generated by MPP into stable mature proteins. This same function of stabilizing proteins, because of removal of a N-terminal residue in proteins imported to mitochondrial matrix, has also been proposed for the recently identified amino peptidase lcp55 [@b0075]. Using proteomic approaches directed to yeast mitochondrial N-terminal sequences, the authors showed that this amino peptidase also acts after MPP processing, by removing one amino acid residue from the newly generated N-terminal. Therefore, some proteins are processed in two steps: the first by MPP followed by oct1 or first by MPP but followed by lcp55. There is also the possibility that some proteins undergo a three step processing MPP-lcp55-oct1, or MPP-oct1-oct1 [@b0065; @b0075].

We recently reported the expression, purification and the partial characterization of recombinant human MIP in *Escherichia coli*, and presented the first continuous activity assay for this peptidase, using the fluorogenic substrate Abz-GFSPFRQ-EDDnp [@b0080]. Only a small level of inhibition was detected with thiorphan (a neprilysin inhibitor) [@b0085] captopril (an angiotensin-converting enzyme inhibitor) [@b0090] and JA-2 (a thimet oligopeptidase inhibitor) [@b0095]. These results exclude *h*MIP as a target of these inhibitors that are used widely to measure TOP (thimet oligopeptidase), ACE (angiotensin-converting enzyme) or NEP (neprilysin) enzymatic activity in cells, tissue sample extracts, and also for *in vivo* inhibition assays. These metallopeptidase inhibitors bear a substrate mimetic portion containing a zinc binding group as warhead. A good understanding of the substrate specificity of *h*MIP can guide the design of new selective inhibitors containing this zinc binding group as warhead.

Knowledge about the substrate specificity of peptidases is essential to identify their roles in mammalian organisms and to aid in the development of selective assays. FRET substrates are useful tools to evaluate the substrate specificity of MIP and an important step for the development of specific inhibitors. Because MIP activity contributes to the mitochondrial iron uptake it has been proposed that the inhibition of MIP might decrease the mitochondrial iron accumulation, a disease known as Friedreich's ataxia, and this could attenuate some complications of this neurodegenerative disease [@b0100].

In the present work, we studied the substrate specificity of recombinant human MIP (*h*MIP), using the synthetic support bond FRET peptide library approach. This support-bound FRET peptide library was prepared on polyethylene glycol dimethyl acrylamide copolymer (PEGA) beaded resin by the process of split-combine synthesis, which results in a single peptide sequence on each bead [@b0105; @b0110; @b0115; @b0120]. Seven positions (X1--X7) were randomized using all 20 genetically encoded amino acids. FRET peptides when hydrolysed by the peptidase turned the bead fluorescent and these beads were manually picked, the remaining peptide was sequenced by Edman degradation methodology. In this approach the enzymatic reaction is terminated before complete hydrolysis of all the peptide attached to a single bead, so each bead contained both the complete peptide sequence as well as the sequences of the remaining portion of the cleaved peptide (S′ amino acids). Thus, is possible to obtain the peptide sequence and the cleavage site using this experimental approach.

9 identified peptides using this approach were synthesized, the *h*MIP cleavage sites and the kinetic parameters evaluated. Additional kinetic analyses were also carried out, using synthetic fluorogenic substrates based on the processing sites attributed to MIP for the precursor nuclear encoded proteins. The data of these substrates gave further insights into the *h*MIP substrate specificity.

2. Results and discussion {#s0010}
=========================

2.1. Support-bound FRET peptide library screening {#s0015}
-------------------------------------------------

The results of the Edman degradation analysis of the fluorescent beads collected in the synthetic support-bound FRET peptide library screening with *h*MIP are shown in [Table S1](#s0085){ref-type="sec"}. The results of this assay clearly showed that MIP hydrolysed preferentially the peptides presenting uncharged polar residues at both P~1~ and P~1~′ positions, especially Ser, Thr and Gln ([Tables S1, S2](#s0085){ref-type="sec"} and [Table 1](#t0005){ref-type="table"}). Thr and Ser are also the preferred residues found in the P~2~′ position ([Table 1](#t0005){ref-type="table"}). Beyond the clear preference for uncharged polar residues at positions P~1~, P~1~′ and P~2~′, some other determinants of specificity were also observed for *h*MIP in the assays: *h*MIP prefers nonpolar residues at the P~3~, P~2~, and P~3~′ substrate positions ([Table 1](#t0005){ref-type="table"}). However, the occurrence of the basic residue Lys at position P~2~′ and P~3~′ is significant ([Table 1](#t0005){ref-type="table"}).

Based on the results obtained in the support-bound FRET peptide library screening 9 new FRET substrates were synthesized. The sequences are shown in [Table 2](#t0010){ref-type="table"}, these FRET substrates were assayed in solution with *h*MIP, and the kinetic parameters for the hydrolysis reactions are presented in [Table 2](#t0010){ref-type="table"}. All substrates were hydrolysed by *h*MIP; 5 of them at the same site as it occurred in the solid-phase support, but 4 were cleaved at a different site or presented additional cleavages by MIP. However, despite these differences between the cleavage sites observed after the kinetic assays in the FRET substrates and the cleavage sites detected in the support bound peptide only the substrates 6 and 12 were not hydrolysed with uncharged polar residues at P~1~ or P~1~′.

For the substrates 4 and 12 more than one cleavage site were detected ([Table 2](#t0010){ref-type="table"}), analysis of product formation in time using HPLC revealed that for the both substrates the peaks corresponding to the products appears simultaneously indicating that no subsequent cleavage of the products occurs. These data together with a description that MIP can act on some FRET substrates described for the thimet oligopeptidase (TOP) and neurolysin (NEL) [@b0080], oligopeptidases that are members of MIP peptidase family, shows that MIP is able to act on peptides releasing products with different lengths, not only 8-mer peptides. A possible explanation for those observations is that when acting on the N-terminal of large proteins MIP probably presents some ruler-like interaction but when small substrates are free to find their way into the MIP active site fewer interactions seems to be necessary to the formation of a productive enzyme-substrate complex. Unfortunately this characteristic of MIP cannot be interpreted in details, since the 3D structure of MIP has not been determined so far.

Therefore, also in the case of these small substrates in solution, which are free to access the *h*MIP extended substrate binding site with multiple possibilities of interaction it can be observed that uncharged polar residues are preferred at P~1~ and/or P~1~′ substrate positions ([Table 2](#t0010){ref-type="table"}).

2.2. Specificity analysis based on natural substrates {#s0020}
-----------------------------------------------------

Joseph et al. analyse the sequences of proteins known as substrates for MIP and identified some conserved positions [@b0125], with respect to the cleaved bond. These conserved positions are F/L/I at P~8~ and T/S/G at P~5~. Reanalysing both predicted and confirmed MIP cleavage sites on 19 precursor proteins, we noted that 14 (\>70%) of them have polar uncharged residues at P~1~ and/or the P~1~′ positions [@b0125] ([Table 3](#t0015){ref-type="table"} and [Table S3](#s0085){ref-type="sec"}), results in line with the outcome of the support-bound FRET peptide library presented above ([Table 1](#t0005){ref-type="table"}).

The substrate binding preference of the P~3~--P~3~′ sites of MIP are presented in the [Fig. 1](#f0005){ref-type="fig"}, based on the data obtained from the synthetic support-bound FRET peptide library, the hydrolysis of the 9 small FRET substrate in solution, and the sequences of precursor proteins that have confirmed the second step of cleavage by MIP [@b0125] ([Table S3](#s0085){ref-type="sec"}). This analysis corroborates the preference for nonpolar residues at the P~2~ position; the occurrence of nonpolar or basic residues at the P~2~′, detected in the support-bound FRET peptide analysis, and the clear preference for uncharged polar residues at positions P~1~ and P~1~′ ([Fig. 1](#f0005){ref-type="fig"}).

Recently MIP processing sites were studied in details for yeast mitochondria imported proteins [@b0070]. This study revealed important observations about the yeast MIP -- the so-called oct1 -- to light. [Table 4](#t0020){ref-type="table"} shows the MPP processing sites together with the MIP processing sites in 14 mitochondrial yeast proteins. Again F/L at the position −8 and T/S at −5 seem to be determinants to MPP/MIP activities ([Table 4](#t0020){ref-type="table"} and [Table S4](#s0085){ref-type="sec"}). Furthermore, Isaya et al. described additional evidences that hydrophobic amino acid positioned near the N-terminal residues are crucial for MIP activity [@b0130].

The results described here support the knowledge that MIP can act on small FRET substrates [@b0080] and the importance for the P~1~ and P~1~′ substrate residues, close to the hydrolysed peptide bond. However the impact of this F/L/I at P~8~ and T/S/G at P~5~ positions on the ability of MIP to process small peptides its unknown. To investigate this, we synthesized 2 FRET substrates containing the sequences of precursor proteins -- assumed to be hydrolysed by MIP -- mimicking the predicted processing sites, Abz-FRSGQPLQNKVQLQ-EDDnp (human ornithine transcarbamylase) and Abz-VRTLTINK_EDDnp (yeast pyruvate dehydrogenase E3 subunit). Both substrates were cleaved at the same predicted site, Abz-FRSGQPLQ↓NKVQLQ-EDDnp and Abz-VRTL↓TINK_EDDnp, however in the yeast sequence there is no P~8~ nor Thr or Ser at P~5~. The substrate Abz-FRSGQPLQNKVQLQ-EDDnp is the best substrate for *h*MIP with better specificity constant due to the higher catalytic constant value (*k*~cat~/*K*~M~ = 130 mM^−1^ s^−1^ and *k*~cat~ = 0.122 s^−1^), when compared with kinetic parameters of Abz-VRTLTINK_EDDnp (*k*~cat~/*K*~M~ = 27 and *k*~cat~ = 0.0093). No significant difference on the affinity constant values (*K*~M~) was observed, 0.941 mM^−1^ and 0.35 mM^−1^ respectively.

Based on this observation, some variations of the human ornithine transcarbamylase based substrate, Abz-FRSGQPLQNKVQLQ-EDDnp, were prepared and assayed with *h*MIP. These variants were synthesized with the purpose to analyse the importance of the substrate length, especially the impact of both P~5~ and P~8~ positions, and also the importance of the residues at P~1~ and/or P~1~′ positions. Furthermore, these new variants could be an interesting starting point for the development of new specific FRET substrates for MIP activity detection assays. The data of these new substrates, the results of cleavage site and kinetic parameters are presented in [Table 5](#t0025){ref-type="table"}. The kinetic assays with the variants of the Abz-FRSGQPLQNKVQLQ-EDDnp gave all similar results. The smaller variants Abz-QPLQNKVQ-EDDnp, Abz-QPLANKVQ-EDDnp and Abz-QPLQAKVQ-EDDnp, were all cleaved at the same site. However, the analogue Abz-QPLQNKVQ-EDDnp, without the P~8~ and P~5~, was hydrolysed with a 7-fold lower specificity constant than Abz-FRSGQPLQNKVQLQ-EDDnp ([Table 5](#t0025){ref-type="table"}). Almost no significant difference in the *k*~cat~ values and *K*~M~ constants were observed when the P~1~ or the P~1~′ polar residues were replaced by an Ala residue ([Table 5](#t0025){ref-type="table"}). Thus the preference of *h*MIP for the polar uncharged residues at these positions is not absolute, an observation in line with the analysis of the predicted MIP processing sites ([Table 3](#t0015){ref-type="table"}), the presence of other residues, specially Ala, are found in the MIP cleavage site, in some processed proteins ([Table 3](#t0015){ref-type="table"} and [Table S3](#s0085){ref-type="sec"}).

3. Conclusions {#s0025}
==============

The *h*MIP substrate specificity was first investigated using synthetic support-bound FRET peptide library screening, the results obtained in this entire randomized approach revealed the *h*MIP preferences for substrate residues close to the hydrolysed peptide bond, with a clear preference for uncharged polar residues at positions P~1~ and P~1~ and nonpolar residues at the substrate P~3~, P~2~, P~2~′ and P~3~′ positions, matching exactly the analysis of the cleavage sites predicted to be natural substrates for *h*MIP.

The results of the specificity analysis using FRET substrates based on natural substrates, support the information that *h*MIP can act upon small substrates, as well as that for recognition and processing small peptides the most important conserved position (F/L/I at P~8~ and T/S/G at P~5~) are not crucial, as in the case of the action by *h*MIP on the N-terminal of large proteins. This observation together with the distinct substrate specificity presented by *h*MIP, specially its preference for polar uncharged residues at P~1~ and P~1~′ positions, can be important information for the development of substrates and inhibitors specific for *h*MIP.

4. Experimental procedures {#s0030}
==========================

4.1. Construction of the expression vector {#s0035}
------------------------------------------

The *h*MIP cDNA fragment (∼2000 bp) was amplified by PCR using the clone, ID 4053687, from the Mammalian Gene Collection (MGC) of Invitrogen. The construct pET28-MIP, which produces *h*MIP with a hexahistidine tag at its N-terminus instead of the residues that correspond to the mitochondrial signal sequence, has already been previously described by our group [@b0080].

4.2. Expression of recombinant *h*MIP {#s0040}
-------------------------------------

*E. coli* BL21 (DE3) pLysS (Novagen) was used as the expression host. *E. coli* cells were incubated overnight at 30 °C and shaken at 150 rpm in 10 mL of Luria-broth (LB) medium, containing kanamycin (50 μg/mL) and chloramphenicol (50 μg/mL). These cells were transferred to 1 L of fresh LB medium at 30 °C and 150 rpm, until the culture density reached 0.4 OD~550~. The temperature was then reduced to 20 °C and when the culture density reached 0.6--0.7 OD~550~ isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.1 mM. After 14--16 h, the bacterial cells were harvested by centrifugation at 5000 rpm, for 10 min, at 4 °C. The pellet was stored at −70 °C.

4.3. Purification of the recombinant *h*MIP {#s0045}
-------------------------------------------

The pellet was resuspended in 20 mL binding buffer (50 mM NaH~2~PO~4~, 500 mM NaCl, 20 mM imidazole, pH 8.0), and lysozyme (1 mg/mL). This suspension was put on ice for 30 min and then RNase and DNase (to a final concentration of 5 μg/mL each), and 2 mL of 0.2% Triton X-100 were added. The resultant mixture was centrifuged at 15,000 rpm for 20 min and the supernatant was recovered.

The supernatant was loaded at a flow rate of 0.5 mL/min on a Ni-Sepharose high performance chromatography column (GE Healthcare) previously equilibrated with binding buffer. The column was washed with 5 ml of binding buffer, and the recombinant *h*MIP was eluted, using a segmented step elution with increasing imidazole concentrations (50, 100, 150 and 500 mM) in binding buffer (20 mM NaH~2~PO~4~ pH 8.0, 500 mM NaCl). The recombinant protein eluted between 100 and 150 mM imidazole. Fractions of ∼8--10 mL each, were collected and loaded onto a desalting preparatory column (GE Healthcare), and the fractions containing *h*MIP were recovered.

This desalted samples were loaded at a flow rate of 1.0 mL/min on a resource Q column (1 mL) previously equilibrated with TB buffer (50 mM Tris, pH 7.4). After an initial washing with 6 mL of TB buffer, the elution was performed with 40 mL of a linear gradient with TBS buffer (50 mM Tris--HCl, pH 7.4, 500 mM NaCl). Recombinant *h*MIP eluted between 80 and 200 mM NaCl. The fractions containing homogeneous (SDS--PAGE) recombinant *h*MIP, according to SDS PAGE analysis, were concentrated using an Amicon filtration unit (Millipore Corp.) equipped with a 50 kDa exclusion membrane, and the recovered protein was finally stored in TBS buffer at −70 °C.

4.4. Peptide synthesis {#s0050}
----------------------

Highly sensitive FRET peptides were synthesized by solid-phase procedures, as described elsewhere [@b0135].

4.5. Synthesis of support-bound FRET peptide library {#s0055}
----------------------------------------------------

The syntheses of libraries were carried out manually as previously described [@b0120]. Briefly, the libraries were synthesized using 1 g of PEGA 1900 resin [@b0140] in a 20 column Teflon synthesis block, using protected Fmoc amino acids. The resin was evenly distributed in the 20 wells of the Teflon synthesis block, and Fmoc groups were removed. Prior to coupling, the Fmoc amino acids (1 equiv.) were pre-activated with HOBt (1 equiv.), TBTU (1 equiv.) and NMM (2 equiv.) in DMF (1 ml) for 6 min; on the activated amino acids were added to each of the 20 wells. After the completion of the coupling, the block was filled with DMF up to 1 cm above the top of the wells and inverted. Then, the resin was mixed vigorously by agitation for 30 min in the mixing chamber. The block was again inverted, evenly distributing the resin in the wells for washing and removal of Fmoc group. This procedure was repeated for the incorporation of all the randomized positions. After the randomized positions, the Fmoc-K (Abz-Boc) and Fmoc-K (Dnp) were incorporated. The side chain protecting groups were removed by treatment with a mixture of TFA:thioanisole:ethane dithiol:water (87:5:5:3) for 8 h. The resin was washed with 95% acetic acid (4×), DMF (4×), 5%DIPEA in DMF (3×), DMF (3×), DCM (6×) and finally dried under vacuum.

4.6. Support-bound FRET peptide library screening {#s0060}
-------------------------------------------------

The peptide library screening was carried out as previously described [@b0120]. For all assays, the library beads were washed with water (3×) and the assay buffer (3×) before the addition of the enzyme. The reactions were stopped by dilution with 3 M HCl, and the mixtures were washed thoroughly until pH 5.6 was reached. The beads were transferred to a glass dish and inspected by fluorescence microscopy (Stereo microscope Stemi-Zeiss), and the fluorescent beads were collected and transferred to a TFA-treated cartridge filter for on-resin sequence analysis. The amino acid sequence and cleavage site were determined by Edman degradation using a PPSQ/23 protein sequencer (Shimadzu, Japan). *h*MIP was assayed as follows: 0.5 μM of enzyme was mixed with 50 mg of resin 50 mM Tris, 100 mM NaCl, pH 8.0, at 25 °C for 24 h. The identified peptide sequences susceptible to hydrolysis by *h*MIP were synthesized as FRET Abz-peptidyl-Q-EDDnp peptides and assayed in solution with the enzyme.

4.7. Enzymatic activity assay {#s0065}
-----------------------------

Hydrolysis of the FRET peptides used as substrates for *h*MIP was monitored spectrofluorometrically in a Shimadzu RF-5301PC spectrofluorometer with excitation and emission wavelengths of 320 and 420 nm, respectively. The rate of increase in fluorescence was converted into moles of substrate hydrolysed per second, based on the fluorescence curves of standard peptide solutions, before and after total enzymatic hydrolysis. The enzyme concentration for initial rate determinations was chosen so that \<10% of the substrate was hydrolysed. The activity was measured in the absence or in the presence of the assayed inhibitors [@b0080].

4.8. Determination of peptide cleavage sites {#s0070}
--------------------------------------------

The peptide cleavage sites were identified using mass spectrometry (LCMS-2010 EV Shimadzu, Tokyo, Japan) and/or peptide sequencing, using a PPSQ-23 protein sequencer (Shimadzu, Tokyo, Japan) [@b0080].
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###### 

Substrate preference matrix for *h*MIP.

  --------------
  ![](fx4.gif)
  --------------

Analysis of the frequencies for specific residues at each identified position in the sequences of peptides hydrolysed in the support-bound FRET peptide library screening. Based on the 20 sequences shown in [Table S1](#s0085){ref-type="sec"}. The bottom rows indicate the total number of residues analyzed for each specific position. The background grey scale helps to bring attention to the higher numbers.

###### 

Kinetic parameters for the hydrolysis of FRET peptides by *h*MIP.

  Sequence No.   Substrate                       *k*~cat~ (s^−1^)   *K*~M~ (μM)   *k*~cat~/*K*~M~ (mM^−1^ s^−1^)
  -------------- ------------------------------- ------------------ ------------- -------------------------------------
  1              Abz- VAA↓QTKTK(Dnp)-NH~2~       0.050              10            5.0
  2              Abz-WT↓TGGKAK(Dnp)-NH~2~        0.0033             6.2           0.53
  4              Abz-MT ↓AALK↓ TK(Dnp)-NH~2~     0.19^a^            4.2^a^        45[a](#tblfn1){ref-type="table-fn"}
  5              Abz- IKQ↓SSLLK(Dnp)-NH~2~       0.055              1.1           50
  6              Abz-NLM↓KKSTK(Dnp)-NH~2~        0.028              1.3           22
  8              Abz- FS↓SKTTVK(Dnp)-NH~2~       0.036              1.3           28
  10             Abz-VIS↓SRLEK(Dnp)-NH~2~        0.083              1.9           44
  12             Abz- TTKL↓ K↓ A↓AK(Dnp)-NH~2~   0.070^a^           0.85^a^       82^a^
  14             Abz- FQ↓TKVAAK(Dnp)-NH~2~       0.057              3.4           17

The substrates were synthesized based on the sequences identified in the support-bound FRET peptide library screening. The parameters were calculated as mean value ± SD, which was lower than 10%. ↓ indicates the cleavage site.

Apparent constants determined by following the total product formation.
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Substrate preference matrix for *h*MIP.
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Analysis of the frequencies for specific residues, at each position, in the sequences of predicted MIP processing sites at the newly generated N-terminal by the MPP action on nuclear encoded proteins imported to the mitochondrial matrix [@b0125]. Based on the 19 sequences shown in [Table S3](#s0085){ref-type="sec"}. The background grey scale helps to bring attention to the higher numbers.

###### 

Substrate preference matrix for oct1.

  --------------
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Analysis of the frequencies for specific residues at each position in the sequences of predicted oct1 processing sites at the newly generated N-terminal by the MPP action on nuclear encoded proteins imported to the *S. cerevisiae* mitochondrial matrix [@b0070]. Based on the 14 sequences shown in [Table S4](#s0085){ref-type="sec"}. The background grey scale helps to bring attention to the higher numbers.

###### 

Kinetic parameters for the hydrolysis of FRET peptides by *h*MIP.

  Substrate                    *k*~cat~ (s^−1^)   *K*~M~ (μM)   *k*~cat~/*K*~M~ (mM^−1^ s^−1^)
  ---------------------------- ------------------ ------------- --------------------------------
  Abz-VRNFRSGQPLQ↓NKVQ-EDDnp   0.223              1.80          124
  Abz-FRSGQPLQ↓NKVQLQ-EDDnp    0.122              0.941         130
  Abz-QPLQ↓NKVQ-EDDnp          0.061              2.9           21
  Abz-QPLA↓NKVQ-EDDnp          0.0570             5.1           11
  Abz-QPLQ↓AKVQ-EDDnp          0.0943             3.2           29

The parameters were calculated as mean value ± SD, which was lower than 10%. ↓ indicates the cleavage site.
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